Eli Lilly to acquire SiteOne Therapeutics in a deal worth up to $1 billion, advancing the development of a potential non-opioid treatment for chronic pain.
Breaking The Pain Barrier: Lilly’s Acquisition Of SiteOne Aims For Opioid Alternatives
Where Today's News Shapes Tomorrow
